NRSN Stock — NeuroSense Therapeutics Ltd.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −47%

below

Price vs 50-day avg −28%

below

RSI (14) 40

neutral

MACD trend Positive

52-week position 7%

near low

Momentum

relative strength

Very Weak

1-month return −10%

trailing

6-month return −50%

trailing

YTD return −45%

this year

Relative strength −63%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +2 funds added

Insider flow Accumulating

Net +$400.0K over 90 days · 0% sells

Short interest Falling

1.30% of float · ▼ -10.8% MoM · 2.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

14 holders — mid 3-yr range

Squeeze score 32

low risk · 0–100

Fundamentals

Fair

EPS growth +19%

Y/Y

Free cash flow $-7.7M

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −74%

past year

ATR 15.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 2 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−47% Bearish

Price vs 50-day avg

−28% Bearish

RSI (14)

40 Neutral

MACD trend

Positive Bullish

52-week position

7% Bearish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +2 funds added

Insider flow Accumulating

Net +$400.0K over 90 days · 0% sells

Short interest Falling

1.30% of float · ▼ -10.8% MoM · 2.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

14 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $0 Now $0 · 7% Range high $1

vs 200-day avg -47% vs 50-day avg -28%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NRSN NeuroSense Therapeutics Ltd. this stock	$16.58M	-45.3%	—	—	1.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+19.5%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$81.27B	+2.9%	+20.8%	19.6	2.3%
ARGX Argenx SE	$63.63B	+21.7%	—	—	1.9%
CSLLY Csl Ltd	$59.92B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

14

% held: 1.5%
Net QoQ: +17.6K sh
Top holder: UBS Group AG

Held Float

View

Short & Settlement

Short Interest Falling

Shares short

489.1K

Days to cover: 2.3d
Change: -58.9K sh

View

Short Volume

Short vol %

34%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

1.6K

Value: $782
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

45.2%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$400.0K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Net income (FY)

$-11.1M

EPS diluted: $-0.44

View

Filings

SEC Filings

Latest

6-K

Filed: Aug 27, 2026
This year: 24

View

Exempt Offerings

Offering

$5.0M

Filed: Dec 12, 2024

View

	5D	20D	120D	MTD	YTD
NRSN	+11.7%	-9.6%	-50.0%	-9.6%	-45.3%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	+11.3%	-12.6%	-63.4%	-12.6%	-58.2%

NRSN · NeuroSense Therapeutics Ltd.

Price & Indicators

Up next

Equibles Rating

Technicals

Versus peers

At a glance

Performance